Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
Heron Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 22, 2021
Heron Therapeutics reported fiscal year 2020 executive compensation information on April 22, 2021.
In 2020, six executives at Heron Therapeutics received on average a compensation package of $2.5M, a 21% decrease compared to previous year.
Average pay of disclosed executives at Heron Therapeutics
Barry D. Quart, Chief Executive Officer, received $5.3M in total, which decreased by 9% compared to 2019. 63% of Quart's compensation, or $3.4M, was in option awards. Quart also received $365K in non-equity incentive plan, $677K in salary, $917K in stock awards, as well as $21K in other compensation.
For fiscal year 2020, the median employee pay was $363,920 at Heron Therapeutics. Therefore, the ratio of Barry D. Quart's pay to the median employee pay was 15 to one.
John Poyhonen, President and Chief Commercial Officer, received a compensation package of $2.7M, which decreased by 41% compared to previous year. 61% of the compensation package, or $1.6M, was in option awards.
David Szekeres, Chief Operating Officer, earned $2.5M in 2020.
Kimberly Manhard, Executive Vice President, Drug Development, received $2.2M in 2020, which decreases by 12% compared to 2019.
Lisa Peraza, Chief Accounting Officer, earned $1.6M in 2020.
Robert Hoffman, Chief Financial Officer, received $1M in 2020, which decreases by 49% compared to 2019.
Related executives
Barry Quart
Heron Therapeutics
Chief Executive Officer
John Poyhonen
Heron Therapeutics
President and Chief Commercial Officer
Kimberly Manhard
Heron Therapeutics
Executive Vice President, Drug Development
David Szekeres
Heron Therapeutics
Executive Vice President, Chief Commercial Officer
Lisa Peraza
Heron Therapeutics
Chief Accounting Officer
Robert Hoffman
Heron Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on April 22, 2021.